| OALBX0102 | Transcriptional programs of HIV silencing and cell survival in HIV-infected memory CD4 T cells under antiretroviral therapy | Oral abstract session with live Q&A | Host cellular factors and viral mechanisms of HIV/SIV persistence and latency |
| OALBX0103 | Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident STI's in a randomized trial | Oral abstract session with live Q&A | STIs (including HPV) |
| OALBX0105 | Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE) | Oral abstract session with live Q&A | Viral hepatitis C and other viral hepatitis (e.g., A, B, D, E) |
| OALBX0106 | Trends in PrEP inequity by race and census region, United States, 2012-2021 | Oral abstract session with live Q&A | Scale up of PrEP |
| OALBX0107 | Long acting cabotegravir: updated efficacy and safety results from HPTN 084 | Oral abstract session with live Q&A | Other new HIV prevention tools |
| PELBA01 | Antibody-mediated prevention of vaginal HIV transmission is dictated by IgG subclass in humanized mice | Poster exhibition | Gene therapy |
| PELBA02 | First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV | Poster exhibition | Immunotherapy (including broadly neutralizing antibodies) |
| PELBA03 | In-vitro/ ex-vivo contribution of antiretroviral drug and alcohol exposure to blood-brain barrier disruption: relevance to the pathogenesis of HIV-1 associated neurological disorder | Poster exhibition | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| PELBB01 | Final week 192 results from the ADVANCE trial: first-line TAF/FTC/DTG, TDF/FTC/DTG vs TDF/FTC/EFV | Poster exhibition | Weight gain |
| PELBB02 | Update on neural tube defects with antiretroviral exposure in the Tsepamo Study, Botswana | Poster exhibition | Pregnancy (clinical management issues and pharmacokinetics) and contraception |